In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...

Mounjaro (tirzepatide) is a prescription drug used ... that’s given as an injection under your skin using single-dose, prefilled pens. Mounjaro is available in the following strengths: You ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity ... Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability ...

Tirzepatide is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Obstructive Sleep Apnea. According to GlobalData, Pre-Registration drugs for Obstructive Sleep Apnea ...

Zealthy Weight Loss Overview Cost: $49 for your first month and $135 per month thereafter Types of weight loss medications: ...